IL17A and colitis: In colitis mice, resveratrol treatment increases the number of anti-inflammatory regulatory T cells (CD4+FOXP3+ and CD4+IL-10+) and down-regulates the number of inflammatory T cells, such as Th1 (CD4+IFN-γ+) and Th17 (CD4+IL-17+) cells in MLNs (73).